| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9186332 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(6 months from now) | |
| US8309124 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(6 months from now) | |
| US8394407 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(6 months from now) | |
| US9040085 | HORIZON | Delayed release tablet with defined core geometry |
Apr, 2024
(6 months from now) | |
| US9504699 | HORIZON | Delayed-release glucocorticoid treatment of rheumatoid disease |
Aug, 2027
(3 years from now) | |
| US8168218 | HORIZON | Delayed release tablet with defined core geometry |
Jan, 2028
(4 years from now) | |
Rayos is owned by Horizon.
Rayos contains Prednisone.
Rayos has a total of 6 drug patents out of which 0 drug patents have expired.
Rayos was authorised for market use on 26 July, 2012.
Rayos is available in tablet, delayed release;oral dosage forms.
Rayos can be used as treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet, treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet, treatment of rheumatologic, allergic, pulmonary, gastrointestinal, dermatologic diseases or conditions by the use of a delayed release 5mg prednisone tablet.
The generics of Rayos are possible to be released after 07 January, 2028.
Drugs and Companies using PREDNISONE ingredient
Market Authorisation Date: 26 July, 2012
Treatment: Treatment of diseases or conditions by the use of a delayed-release 1,2, or 5mg prednisone tablet; Treatment of diseases or conditions by the use of a delayed release 1, 2, or 5 mg prednisone tablet; ...
Dosage: TABLET, DELAYED RELEASE;ORAL
RAYOS family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic